Duchenne Gene Therapy SGT-003: 15 Patients Dosed So Far
United States – October 27, 2026 -- Fifteen people with Duchenne muscular dystrophy had received the investigational gene therapy SGT-003 in the INSPIRE DUCHENNE clinical study as of August 12, 2025, according to developer Solid Biosciences.
Ten trial sites span four countries
The multi-center, open-label trial now runs 10 active clinical sites in the United States, Canada, Italy, and the United Kingdom. More sites are expected to open later this year.
Solid Biosciences expects to have treated at least 20 patients aged 0 to under 12 by the end of 2025. It anticipates widening enrollment to older patients in 2026.